Terms: = Prostate cancer AND ZFHX3, ATBT, 463, ENSG00000140836, Q15911 AND Prognosis
13 results:
1. Integrating single-cell and bulk RNA sequencing to predict prognosis and immunotherapy response in prostate cancer.
Wen XY; Wang RY; Yu B; Yang Y; Yang J; Zhang HC
Sci Rep; 2023 Sep; 13(1):15597. PubMed ID: 37730847
[TBL] [Abstract] [Full Text] [Related]
2. Somatic and Germline Variants Affect prognosis and Susceptibility in prostate cancer.
Rocca C; Rocca G; Zampieri P; Dell'atti L; Bianchi N; Ippolito C; Aguiari G
Anticancer Res; 2023 Jul; 43(7):2941-2949. PubMed ID: 37351993
[TBL] [Abstract] [Full Text] [Related]
3. PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer.
Scheinberg T; Lin HM; Fitzpatrick M; Azad AA; Bonnitcha P; Davies A; Heller G; Huynh K; Mak B; Mahon K; Sullivan D; Meikle PJ; Horvath LG
Prostate Cancer Prostatic Dis; 2024 Mar; 27(1):136-143. PubMed ID: 37147359
[TBL] [Abstract] [Full Text] [Related]
4. A circadian rhythm-related gene signature for predicting relapse risk and immunotherapeutic effect in prostate adenocarcinoma.
Liu J; Tan Z; Yang S; Song X; Li W
Aging (Albany NY); 2022 Sep; 14(17):7170-7185. PubMed ID: 36103249
[TBL] [Abstract] [Full Text] [Related]
5. Detection of disease-causing mutations in prostate cancer by NGS sequencing.
Mangolini A; Rocca C; Bassi C; Ippolito C; Negrini M; Dell'Atti L; Lanza G; Gafà R; Bianchi N; Pinton P; Aguiari G
Cell Biol Int; 2022 Jul; 46(7):1047-1061. PubMed ID: 35347810
[TBL] [Abstract] [Full Text] [Related]
6. An organoid-based drug screening identified a menin-MLL inhibitor for endometrial cancer through regulating the HIF pathway.
Chen J; Zhao L; Peng H; Dai S; Quan Y; Wang M; Wang J; Bi Z; Zheng Y; Zhou S; Liu Y; Chen C; Na F
Cancer Gene Ther; 2021 Feb; 28(1-2):112-125. PubMed ID: 32632269
[TBL] [Abstract] [Full Text] [Related]
7. Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer.
Du M; Tian Y; Tan W; Wang L; Wang L; Kilari D; Huang CC; Wang L; Kohli M
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):705-713. PubMed ID: 32203070
[TBL] [Abstract] [Full Text] [Related]
8. Peripheral blood monocyte count reflecting tumor-infiltrating macrophages is a predictive factor of adverse pathology in radical prostatectomy specimens.
Hayashi T; Fujita K; Nojima S; Hayashi Y; Nakano K; Ishizuya Y; Wang C; Yamamoto Y; Kinouchi T; Matsuzaki K; Kawamura N; Jingushi K; Kawashima A; Nagahara A; Ujike T; Uemura M; Imamura R; Morii E; Nonomura N
Prostate; 2017 Oct; 77(14):1383-1388. PubMed ID: 28845570
[TBL] [Abstract] [Full Text] [Related]
9. BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer.
Cui M; Gao XS; Gu X; Guo W; Li X; Ma M; Qin S; Qi X; Xie M; Peng C; Bai Y
Oncotarget; 2017 Jun; 8(25):40222-40232. PubMed ID: 28410213
[TBL] [Abstract] [Full Text] [Related]
10. Patient-Reported Outcomes for Determining Prognostic Groups in Veterans With Advanced cancer.
Chang VT; Scott CB; Gonzalez ML; Einhorn J; Yan H; Kasimis BS
J Pain Symptom Manage; 2015 Sep; 50(3):313-20. PubMed ID: 25912275
[TBL] [Abstract] [Full Text] [Related]
11. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer.
Guzel E; Karatas OF; Semercioz A; Ekici S; Aykan S; Yentur S; Creighton CJ; Ittmann M; Ozen M
Int J Cancer; 2015 Feb; 136(4):875-9. PubMed ID: 24976077
[TBL] [Abstract] [Full Text] [Related]
12. A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.
Amin Al Olama A; Kote-Jarai Z; Schumacher FR; Wiklund F; Berndt SI; Benlloch S; Giles GG; Severi G; Neal DE; Hamdy FC; Donovan JL; Hunter DJ; Henderson BE; Thun MJ; Gaziano M; Giovannucci EL; Siddiq A; Travis RC; Cox DG; Canzian F; Riboli E; Key TJ; Andriole G; Albanes D; Hayes RB; Schleutker J; Auvinen A; Tammela TL; Weischer M; Stanford JL; Ostrander EA; Cybulski C; Lubinski J; Thibodeau SN; Schaid DJ; Sorensen KD; Batra J; Clements JA; Chambers S; Aitken J; Gardiner RA; Maier C; Vogel W; Dörk T; Brenner H; Habuchi T; Ingles S; John EM; Dickinson JL; Cannon-Albright L; Teixeira MR; Kaneva R; Zhang HW; Lu YJ; Park JY; Cooney KA; Muir KR; Leongamornlert DA; Saunders E; Tymrakiewicz M; Mahmud N; Guy M; Govindasami K; O'Brien LT; Wilkinson RA; Hall AL; Sawyer EJ; Dadaev T; Morrison J; Dearnaley DP; Horwich A; Huddart RA; Khoo VS; Parker CC; Van As N; Woodhouse CJ; Thompson A; Dudderidge T; Ogden C; Cooper CS; Lophatonanon A; Southey MC; Hopper JL; English D; Virtamo J; Le Marchand L; Campa D; Kaaks R; Lindstrom S; Diver WR; Gapstur S; Yeager M; Cox A; Stern MC; Corral R; Aly M; Isaacs W; Adolfsson J; Xu J; Zheng SL; Wahlfors T; Taari K; Kujala P; Klarskov P; Nordestgaard BG; Røder MA; Frikke-Schmidt R; Bojesen SE; FitzGerald LM; Kolb S; Kwon EM; Karyadi DM; Orntoft TF; Borre M; Rinckleb A; Luedeke M; Herkommer K; Meyer A; Serth J; Marthick JR; Patterson B; Wokolorczyk D; Spurdle A; Lose F; McDonnell SK; Joshi AD; Shahabi A; Pinto P; Santos J; Ray A; Sellers TA; Lin HY; Stephenson RA; Teerlink C; Muller H; Rothenbacher D; Tsuchiya N; Narita S; Cao GW; Slavov C; Mitev V; ; ; ; ; Chanock S; Gronberg H; Haiman CA; Kraft P; Easton DF; Eeles RA
Hum Mol Genet; 2013 Jan; 22(2):408-15. PubMed ID: 23065704
[TBL] [Abstract] [Full Text] [Related]
13. Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis.
Livsey JE; Cowan RA; Wylie JP; Swindell R; Read G; Khoo VS; Logue JP
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1254-9. PubMed ID: 14630259
[TBL] [Abstract] [Full Text] [Related]
